%0 Journal Article %1 Delbaldo.2005 %A Delbaldo, C. %A Pierga, J. Y. %A Dieras, V. %A Faivre, S. %A Laurence, V. %A Vedovato, J. C. %A Bonnay, M. %A Mueser, M. %A Nolting, A. %A Kovar, A. %A Raymond, E. %D 2005 %J Eur.J.Cancer %K & Adenocarcinoma Adult Aged Antibodies Antineoplastic Area Assay Camptothecin Chemotherapy Colorectal Combined Curve Enzyme-Linked Epidermal Factor Female Growth Humans Immunosorbent Male Middle Monoclonal Neoplasms Pharmacokinetics Protocols Receptor Research Under administration analogs derivatives dosage drug metabolism therapeutic therapy use %N 12 %P 1739-1745 %T Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma %U PM:16051481 %V 41 %X This trial assessed pharmacokinetic interactions between cetuximab and irinotecan. Patients were placed in either in group A (irinotecan 350 mg/m2/3 weeks and 400 mg/m2 cetuximab at week 2 then 250 mg/m2/week) or group B (cetuximab weekly starting week 1 then irinotecan starting week 4). Patient plasma or serum samples from each treatment arm were analysed using HPLC and ELISA. Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively. Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4. Mean concentration-versus-time profiles either alone or in combination were superimposable for cetuximab and irinotecan. From this study, we conclude that there is no evidence of pharmacokinetic interaction

@article{Delbaldo.2005, abstract = {This trial assessed pharmacokinetic interactions between cetuximab and irinotecan. Patients were placed in either in group A (irinotecan 350 mg/m2/3 weeks and 400 mg/m2 cetuximab at week 2 then 250 mg/m2/week) or group B (cetuximab weekly starting week 1 then irinotecan starting week 4). Patient plasma or serum samples from each treatment arm were analysed using HPLC and ELISA. Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively. Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4. Mean concentration-versus-time profiles either alone or in combination were superimposable for cetuximab and irinotecan. From this study, we conclude that there is no evidence of pharmacokinetic interaction}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Delbaldo, C. and Pierga, J. Y. and Dieras, V. and Faivre, S. and Laurence, V. and Vedovato, J. C. and Bonnay, M. and Mueser, M. and Nolting, A. and Kovar, A. and Raymond, E.}, biburl = {https://www.bibsonomy.org/bibtex/2b7576edfa5e22c9523765d29cd2ddc7d/kanefendt}, interhash = {54f2c820241fd7b0766819f3537263b0}, intrahash = {b7576edfa5e22c9523765d29cd2ddc7d}, journal = {Eur.J.Cancer}, keywords = {& Adenocarcinoma Adult Aged Antibodies Antineoplastic Area Assay Camptothecin Chemotherapy Colorectal Combined Curve Enzyme-Linked Epidermal Factor Female Growth Humans Immunosorbent Male Middle Monoclonal Neoplasms Pharmacokinetics Protocols Receptor Research Under administration analogs derivatives dosage drug metabolism therapeutic therapy use}, number = 12, pages = {1739-1745}, timestamp = {2010-02-05T11:28:42.000+0100}, title = {Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma}, url = {PM:16051481}, volume = 41, year = 2005 }